Trio Resources (TRII) Begins Automating Mineral Processing

Posted by Colleen Koski

October 24, 2013 at 11:55 AM

Earlier this week, Trio Resources, Inc. (TRII-OTC) announced that it has started the process of automating a mill that was recently purchased for its Duncan-Kerr Property. Trio is a Canadian exploration-stage and small-scale processing company focused on developing the current mineral potential of historically rich mining regions. 

Read More

Topics: Trio Resources

T3 Motion Creates National Service Program for its Electric Vehicles

Posted by Colleen Koski

October 23, 2013 at 5:11 PM

Yesterday, T3 Motion, Inc. (TTTM-OTC) announced plans to offer service and preventative maintenance for its electric vehicles through a nationwide program—known as T3 Fleet Services. The program is set to launch November 1st in the Western region of the U.S., with plans to expand services nationally by year’s end.

The benefits of the T3 Fleet Services program include:

Read More

Topics: T3 Motion

Neonode (NEON): Next-Gen Chip Release and New Markets Fuel Growth

Posted by Colleen Koski

October 21, 2013 at 9:37 AM

Neonode Inc. (NEON-NASDAQ), a company that specializes in touch-sensing technologies for electronic devices, continues to improve its proprietary platform technology while expanding its potential applications. The Company’s patented MultiSensing® Technology enables users to interact with electronic devices by touching areas on a screen. Neonode’s technology recognizes any object (e.g., finger, stylus) and supports multiple touches on the screen simultaneously. It can sense an object’s size, pressure on a surface, depth, velocity, or proximity to the screen’s surface.

Second-Gen Chip Improves Touchscreen Performance, Cost, and Function

Read More

Topics: Neonode Inc.

CardioComm’s HeartCheck™ Proven Valuable in Large-Scale Study

Posted by Colleen Koski

October 18, 2013 at 10:13 AM

Read More

Topics: CardioComm Solutions

ISCO: New Preclinical Data, Continued Progress for Parkinson's Program

Posted by Colleen Koski

October 16, 2013 at 11:53 AM

International Stem Cell Corp. (ISCO-OTCQB) has announced new results from its preclinical Parkinson's disease program. ISCO is developing a novel approach that uses self-renewing human parthenogenetic neural stem cells (hPNSCs), which are derived from the Company’s proprietary histocompatible human pluripotent stem cells, to treat Parkinson’s disease. Parkinson's disease is a progressive disorder of the nervous system that affects four million to six million people worldwide (Source: National Parkinson Foundation). It belongs to a group of motor system disorders that result from the loss of dopamine-producing cells in the brain.

ISCO is currently evaluating its Parkinson's therapy in final preclinical primate studies. Data collected as part of a collaboration with the Sanford Burnham Medical Research Institute, summarized below, was announced at the American Neurological Association's 2013 Annual Meeting in New Orleans.

  • The neural stem cells were shown to migrate a significant distance from the site of implantation (in the striatum) to the main region where the loss of dopamine-releasing (“dopaminergic”) neurons occurs in Parkinson's patients—the substantia nigra. No evidence of migration outside the brain was observed.
  • Regarding safety, ISCO’s neural stem cells elicited a lower immunogenic response versus other cell types included in the study.
  • The study conclusively demonstrated that the neural stem cells were able to differentiate into the specific type of neurons lost in Parkinson’s disease.
Read More

Topics: ISCO

AtheroNova Announces New Member of Clinical Advisory Board

Posted by Karen Goldfarb

October 15, 2013 at 1:28 PM

Read More

Topics: AtheroNova

"The Smart Money is Heading Outside the U.S." - CNBC

Posted by Laura Swartz

October 14, 2013 at 3:38 PM

Global Equity Investing

Read More

Topics: Newsworthy Events

Is Pharma Forecasting No Longer to be Trusted? McKinsey & Co. says Yes.

Posted by Laura Swartz

October 9, 2013 at 2:06 PM

Developing sales forecasts has long been a crucial piece of the pharmaceutical development puzzle. Pharma companies use these forecasts to guide decisions at every stage of product development, from what drugs to develop and what technologies to license to how clinical trials should be designed and how sales resources are deployed. Yet last week, a study of more than 1,700 individual analyst forecasts on 260 launched drugs was published in Nature Reviews Drug Discovery, definitively finding that most consensus forecasts are wrong.

Read More

Topics: Newsworthy Events

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic